Serveur d'exploration sur l'Indium

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Technetium-99m antimyosin antibody (3–48) myocardial imaging: human biodistribution, safety and clinical results in detection of acute myocardial infarction

Identifieur interne : 000085 ( Main/Exploration ); précédent : 000084; suivant : 000086

Technetium-99m antimyosin antibody (3–48) myocardial imaging: human biodistribution, safety and clinical results in detection of acute myocardial infarction

Auteurs : RBID : ISTEX:259_1995_Article_BF00839060.pdf

English descriptors

Abstract

Technetium-99m antimyosin (99mTc-AM) antibody imaging may have significant advantages over indium-111 antimyosin in clinical practice. The purpose of this study was to determine the human biodistribution, the safety profile and the sensitivity of99mTc-AM (3–48) imaging in the detection of both Q-wave and non-Q-wave myocardial infarction (MI). Biodistribution and safety parameters were mainly determined in 12 normal healthy volunteers while 40 patients with proven MI (22 Q-wave, 18 non-Q-wave) were injected with99mTc-AM (20–25 mCi) between 5 h and 7 days after the onset of acute chest pain. Three standard planar views were performed at 6 h and at 24 h post injection. Both sets of images were completed in 33 patients while two patients were imaged only at 6 h, three patients only at 18 h and one at 18 and 24 h. One patient was not imaged. Vital signs and ECG were recorded and blood samples for haematology, biochemistry and human antimurine antibodies (HAMA) and urinalysis were obtained in all volunteers and patients. No serious adverse reactions or side-effects attributable to99mTc-AM have been reported. No volunteers or patients developed allergic reactions or significant increases in HAMA titres. Reading of99mTc-AM imaging was performed by two blinded experienced observers. The sensitivity of99mTc-AM in the detection of MI was 100% (21/21) for Q-wave and 83.3% (15/18) for non-Q-wave infarctions. The overall sensitivity was 92.3% (36/39). The three false-negative cases were inferoposterior MI. A certain degree of uptake focalization was seen in 26 out of 35 (74.2%) at 6 h. At 24 h, two patients (5.8%) did not show99mTc-AM uptake while 22 (64.7%) showed intense focal uptake, seven (20.6%) moderate uptake and 3 (8.9%) slight uptake. It is concluded that99mTc-AM (3–48) imaging is safe and shows high sensitivity in the detection of both Q-wave and non-Q-wave MI even with early imaging (6 h post injection). These promising results warrant further clinical investigation.

DOI: 10.1007/BF00839060

Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title>Technetium-99m antimyosin antibody (3–48) myocardial imaging: human biodistribution, safety and clinical results in detection of acute myocardial infarction</title>
<author>
<name>Raymond Taillefer</name>
<affiliation wicri:level="1">
<mods:affiliation>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author>
<name>Luc Boucher</name>
<affiliation wicri:level="1">
<mods:affiliation>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author>
<name>Raymond Lambert</name>
<affiliation wicri:level="1">
<mods:affiliation>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author>
<name>Jean Grégoire</name>
<affiliation wicri:level="1">
<mods:affiliation>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author>
<name>Denis-Carl Phaneuf</name>
<affiliation wicri:level="1">
<mods:affiliation>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author>
<name>Hanna Sikorsa</name>
<affiliation wicri:level="1">
<mods:affiliation>Rougier Bio-Tech Ltd., Montréal, Canada</mods:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Rougier Bio-Tech Ltd., Montréal</wicri:regionArea>
<placeName>
<settlement type="city">Montréal</settlement>
<region type="state">Québec</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="RBID">ISTEX:259_1995_Article_BF00839060.pdf</idno>
<date when="1995">1995</date>
<idno type="doi">10.1007/BF00839060</idno>
<idno type="wicri:Area/Main/Corpus">000869</idno>
<idno type="wicri:Area/Main/Curation">000869</idno>
<idno type="wicri:Area/Main/Exploration">000085</idno>
</publicationStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Myocardial infarction</term>
<term>Technetium-99m antimyosin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="eng">Technetium-99m antimyosin (99mTc-AM) antibody imaging may have significant advantages over indium-111 antimyosin in clinical practice. The purpose of this study was to determine the human biodistribution, the safety profile and the sensitivity of99mTc-AM (3–48) imaging in the detection of both Q-wave and non-Q-wave myocardial infarction (MI). Biodistribution and safety parameters were mainly determined in 12 normal healthy volunteers while 40 patients with proven MI (22 Q-wave, 18 non-Q-wave) were injected with99mTc-AM (20–25 mCi) between 5 h and 7 days after the onset of acute chest pain. Three standard planar views were performed at 6 h and at 24 h post injection. Both sets of images were completed in 33 patients while two patients were imaged only at 6 h, three patients only at 18 h and one at 18 and 24 h. One patient was not imaged. Vital signs and ECG were recorded and blood samples for haematology, biochemistry and human antimurine antibodies (HAMA) and urinalysis were obtained in all volunteers and patients. No serious adverse reactions or side-effects attributable to99mTc-AM have been reported. No volunteers or patients developed allergic reactions or significant increases in HAMA titres. Reading of99mTc-AM imaging was performed by two blinded experienced observers. The sensitivity of99mTc-AM in the detection of MI was 100% (21/21) for Q-wave and 83.3% (15/18) for non-Q-wave infarctions. The overall sensitivity was 92.3% (36/39). The three false-negative cases were inferoposterior MI. A certain degree of uptake focalization was seen in 26 out of 35 (74.2%) at 6 h. At 24 h, two patients (5.8%) did not show99mTc-AM uptake while 22 (64.7%) showed intense focal uptake, seven (20.6%) moderate uptake and 3 (8.9%) slight uptake. It is concluded that99mTc-AM (3–48) imaging is safe and shows high sensitivity in the detection of both Q-wave and non-Q-wave MI even with early imaging (6 h post injection). These promising results warrant further clinical investigation.</div>
</front>
</TEI>
<mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="97c5249be7cbe5ef17701a395f7bae88ea4ed28a">
<titleInfo lang="eng">
<title>Technetium-99m antimyosin antibody (3–48) myocardial imaging: human biodistribution, safety and clinical results in detection of acute myocardial infarction</title>
</titleInfo>
<name type="personal">
<namePart type="given">Raymond</namePart>
<namePart type="family">Taillefer</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec, Canada</affiliation>
</name>
<name type="personal">
<namePart type="given">Luc</namePart>
<namePart type="family">Boucher</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec, Canada</affiliation>
</name>
<name type="personal">
<namePart type="given">Raymond</namePart>
<namePart type="family">Lambert</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec, Canada</affiliation>
</name>
<name type="personal">
<namePart type="given">Jean</namePart>
<namePart type="family">Grégoire</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec, Canada</affiliation>
</name>
<name type="personal">
<namePart type="given">Denis-Carl</namePart>
<namePart type="family">Phaneuf</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Département de Médecine Nucléaire, Hôtel-Dieu de Montréal, 3840 St. Urbain, H2W 1T8, Montréal, Québec, Canada</affiliation>
</name>
<name type="personal">
<namePart type="given">Hanna</namePart>
<namePart type="family">Sikorsa</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Rougier Bio-Tech Ltd., Montréal, Canada</affiliation>
</name>
<typeOfResource>text</typeOfResource>
<genre>Original Article</genre>
<genre>Original Paper</genre>
<originInfo>
<publisher>Springer-Verlag, Berlin/Heidelberg</publisher>
<dateCreated encoding="w3cdtf">1994-11-16</dateCreated>
<dateValid encoding="w3cdtf">2004-12-01</dateValid>
<copyrightDate encoding="w3cdtf">1995</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<internetMediaType>text/html</internetMediaType>
</physicalDescription>
<abstract lang="eng">Technetium-99m antimyosin (99mTc-AM) antibody imaging may have significant advantages over indium-111 antimyosin in clinical practice. The purpose of this study was to determine the human biodistribution, the safety profile and the sensitivity of99mTc-AM (3–48) imaging in the detection of both Q-wave and non-Q-wave myocardial infarction (MI). Biodistribution and safety parameters were mainly determined in 12 normal healthy volunteers while 40 patients with proven MI (22 Q-wave, 18 non-Q-wave) were injected with99mTc-AM (20–25 mCi) between 5 h and 7 days after the onset of acute chest pain. Three standard planar views were performed at 6 h and at 24 h post injection. Both sets of images were completed in 33 patients while two patients were imaged only at 6 h, three patients only at 18 h and one at 18 and 24 h. One patient was not imaged. Vital signs and ECG were recorded and blood samples for haematology, biochemistry and human antimurine antibodies (HAMA) and urinalysis were obtained in all volunteers and patients. No serious adverse reactions or side-effects attributable to99mTc-AM have been reported. No volunteers or patients developed allergic reactions or significant increases in HAMA titres. Reading of99mTc-AM imaging was performed by two blinded experienced observers. The sensitivity of99mTc-AM in the detection of MI was 100% (21/21) for Q-wave and 83.3% (15/18) for non-Q-wave infarctions. The overall sensitivity was 92.3% (36/39). The three false-negative cases were inferoposterior MI. A certain degree of uptake focalization was seen in 26 out of 35 (74.2%) at 6 h. At 24 h, two patients (5.8%) did not show99mTc-AM uptake while 22 (64.7%) showed intense focal uptake, seven (20.6%) moderate uptake and 3 (8.9%) slight uptake. It is concluded that99mTc-AM (3–48) imaging is safe and shows high sensitivity in the detection of both Q-wave and non-Q-wave MI even with early imaging (6 h post injection). These promising results warrant further clinical investigation.</abstract>
<subject lang="eng">
<genre>Key words</genre>
<topic>Technetium-99m antimyosin</topic>
<topic>Myocardial infarction</topic>
</subject>
<relatedItem type="series">
<titleInfo type="abbreviated">
<title>Eur J Nucl Med</title>
</titleInfo>
<titleInfo>
<title>European Journal of Nuclear Medicine</title>
<partNumber>Year: 1995</partNumber>
<partNumber>Volume: 22</partNumber>
<partNumber>Number: 5</partNumber>
</titleInfo>
<genre>Archive Journal</genre>
<originInfo>
<dateIssued encoding="w3cdtf">1995-05-01</dateIssued>
<copyrightDate encoding="w3cdtf">1995</copyrightDate>
</originInfo>
<subject usage="primary">
<topic>Medicine & Public Health</topic>
<topic>Imaging / Radiology</topic>
<topic>Nuclear Medicine</topic>
</subject>
<identifier type="issn">0340-6997</identifier>
<identifier type="issn">Electronic: 1619-7089</identifier>
<identifier type="matrixNumber">259</identifier>
<identifier type="local">IssueArticleCount: 18</identifier>
<recordInfo>
<recordOrigin>Springer-Verlag, 1995</recordOrigin>
</recordInfo>
</relatedItem>
<identifier type="doi">10.1007/BF00839060</identifier>
<identifier type="matrixNumber">Art9</identifier>
<identifier type="local">BF00839060</identifier>
<accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition>
<accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition>
<accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition>
<part>
<extent unit="pages">
<start>453</start>
<end>464</end>
</extent>
</part>
<recordInfo>
<recordOrigin>Springer-Verlag, 1995</recordOrigin>
<recordIdentifier>259_1995_Article_BF00839060.pdf</recordIdentifier>
</recordInfo>
</mods>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000085 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000085 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:259_1995_Article_BF00839060.pdf
   |texte=   Technetium-99m antimyosin antibody (3–48) myocardial imaging: human biodistribution, safety and clinical results in detection of acute myocardial infarction
}}

Wicri

This area was generated with Dilib version V0.5.81.
Data generation: Mon Aug 25 10:35:12 2014. Site generation: Thu Mar 7 10:08:40 2024